Trials / Withdrawn
WithdrawnNCT02095574
A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma
Disposition of [14C] ABT-199 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Following a Single Oral Dose Administration
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A pharmacokinetic study to access how the body absorbs and removes ABT-199 in adults with Non-Hodgkin's Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]ABT-199 (GDC-0199) | \[14C\]ABT-199 will be administered as a single oral administration |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2014-09-01
- Completion
- 2015-01-01
- First posted
- 2014-03-26
- Last updated
- 2014-08-13
Source: ClinicalTrials.gov record NCT02095574. Inclusion in this directory is not an endorsement.